Zydus Lifesciences Ltd Q4 FY25 Results

Summary

Zydus Lifesciences Ltd has announced its financial results for Q4 FY25 and the full year, with a 1100% dividend. The company reported an 18% YoY growth in Q4 revenue, standing at Rs. 65,279 mn. The full year revenue was up 19% YoY, reaching Rs. 2,32,415 mn. EBITDA for the quarter was up 30% YoY, and the net profit, adjusted for exceptional items, was up 18% YoY. The company's net debt to equity ratio as on 31st March, 2025 was -0.20x, and net cash as on March 31, 2025 was Rs. 48,836 mn.

Key Highlights

1. 1

   Q4 FY25 Revenue from operations at Rs. 65,279 mn, up 18% over last year

2. 2

   Research & Development (R&D) investments for the quarter stood at Rs. 4,799 mn (7.4% of revenues)

3. 3

   EBITDA for the quarter was Rs. 21,255 mn, up 30% YoY

4. 4

   EBITDA margin for the quarter stood at 32.6%, which is an improvement of 310 bps on a YoY basis

5. 5

   Net Profit, adjusted for exceptional items, was Rs. 13,905 mn, up 18% YoY

6. 6

   Full Year FY25 Revenue from operations at Rs. 2,32,415 mn, up 19% over last year

7. 7

   Research & Development (R&D) investments for the year stood at Rs. 18,555 mn (8.0% of revenues)

8. 8

   EBITDA for the year was Rs. 70,585 mn, up 31% YoY

9. 9

   EBITDA margin for the year stood at 30.4%, which is an improvement of 290 bps over the previous year

10. 10

    Net Profit, adjusted for exceptional items, was Rs. 47,451 mn, up 23% YoY

11. 11

    Net Debt to Equity ratio as on 31* March, 2025 was -0.20x

12. 12

    Net Debt to EBITDA stood at -0.69x at the end of March, 2025

13. 13

    Net Cash (negative Net Debt) as on March 31*, 2025 was Rs. 48,836 mn